CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

vedolizumab

Last Updated: August 10, 2020
Result type: Reports
Project Number: SR0647-000
Product Line: Common Drug Review

Generic Name: vedolizumab

Brand Name: Entyvio

Manufacturer: Takeda Canada Inc.

Indications: Crohn’s disease

Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a TNF antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule C

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openMay 05, 2020
Call for patient input closedJune 24, 2020
Clarification:

- Patient input submission received from Crohn’s and Colitis Canada and Gastrointestinal Society

Submission receivedJuly 23, 2020
Submission acceptedAugust 07, 2020
Review initiatedAugust 10, 2020
Draft CADTH review report(s) provided to sponsor for commentOctober 23, 2020
Deadline for sponsors commentsNovember 03, 2020
CADTH responses on draft review report(s) provided to sponsorNovember 27, 2020
Expert committee meeting (initial)December 09, 2020
Draft recommendation issuedDecember 21, 2020
To
December 23, 2020